Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Recurrent vulvovaginal candidiasis lacks effective and convenient management options.
• Current treatments often fail to provide a lasting solution for affected individuals.

Purpose of the Study:

• To evaluate the efficacy of long-term weekly fluconazole in managing recurrent vulvovaginal candidiasis.
• To compare fluconazole's effectiveness against a placebo in preventing disease recurrence.

Main Methods:

• 387 women with recurrent vulvovaginal candidiasis were enrolled.
• Participants received initial open-label fluconazole, followed by weekly fluconazole or placebo for six months.
• Primary outcome was clinical remission at six months; secondary outcomes included 12-month outcomes and mycologic status.

Main Results:

• Weekly fluconazole significantly increased disease-free rates at 6, 9, and 12 months compared to placebo (P<0.001).
• Median time to recurrence was extended to 10.2 months with fluconazole versus 4.0 months with placebo (P<0.001).
• No fluconazole resistance or C. glabrata superinfections were observed; one patient discontinued due to headache.

Conclusions:

• Long-term weekly fluconazole effectively reduces symptomatic recurrence of vulvovaginal candidiasis.
• Achieving a complete long-term cure for recurrent vulvovaginal candidiasis remains a clinical challenge.